|
|
|
A conversation with Elaine Peters and Philipp Hoch, BioPhorum | BioPhorum recently created a resource of potential critical quality attributes (CQAs) for mRNA products from the early stages of drug development to commercial manufacturing. We asked two of the paper’s authors some questions to explore the key areas in more detail. |
|
|
|
By Stephen Albert Johnston, Calviri | Calviri has been developing an RNA vaccine to prevent cancer for more than 20 years, and repeatedly faced the nearly universal belief that it’s impossible. We’ve learned a number of important lessons along the way that are worth imparting to other vaccine developers. |
|
|
|
| Establishing Analytical Methods For mRNA-Based Therapies | White Paper | MilliporeSigma | Here, we provide a detailed description of assays for sequence identification and LNP composition, two CQAs of mRNA-LNP products, that support the development of safe and effective mRNA therapies. |
|
|
| Defining A Process For Your Unique mRNA | Infographic | Sartorius | Define a process for your unique mRNA with this interactive guide to pDNA, mRNA, and LNP. Overcome challenges with solutions that can help you develop a next-generation production strategy. |
|
|
|
.png){kind=logo}
